PMC:7267243 / 13387-14101 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"411","span":{"begin":178,"end":186},"obj":"Species"},{"id":"413","span":{"begin":71,"end":82},"obj":"Species"},{"id":"414","span":{"begin":119,"end":132},"obj":"Chemical"},{"id":"418","span":{"begin":7,"end":16},"obj":"Disease"},{"id":"419","span":{"begin":165,"end":173},"obj":"Disease"},{"id":"424","span":{"begin":424,"end":432},"obj":"Species"},{"id":"425","span":{"begin":310,"end":318},"obj":"Disease"},{"id":"426","span":{"begin":393,"end":401},"obj":"Disease"},{"id":"427","span":{"begin":419,"end":423},"obj":"Disease"},{"id":"436","span":{"begin":606,"end":612},"obj":"Disease"}],"attributes":[{"id":"A411","pred":"tao:has_database_id","subj":"411","obj":"Tax:9606"},{"id":"A413","pred":"tao:has_database_id","subj":"413","obj":"Tax:746128"},{"id":"A414","pred":"tao:has_database_id","subj":"414","obj":"MESH:C012990"},{"id":"A418","pred":"tao:has_database_id","subj":"418","obj":"MESH:D003643"},{"id":"A419","pred":"tao:has_database_id","subj":"419","obj":"MESH:C000657245"},{"id":"A424","pred":"tao:has_database_id","subj":"424","obj":"Tax:9606"},{"id":"A425","pred":"tao:has_database_id","subj":"425","obj":"MESH:C000657245"},{"id":"A426","pred":"tao:has_database_id","subj":"426","obj":"MESH:C000657245"},{"id":"A427","pred":"tao:has_database_id","subj":"427","obj":"MESH:D012128"},{"id":"A436","pred":"tao:has_database_id","subj":"436","obj":"MESH:D000079225"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"crease mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11\nOur findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients.\n\nCONFLICT OF INTEREST\nPK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture"}

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T25","span":{"begin":148,"end":153},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"crease mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11\nOur findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients.\n\nCONFLICT OF INTEREST\nPK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture"}

    LitCovid-PD-UBERON

    {"project":"LitCovid-PD-UBERON","denotations":[{"id":"T19","span":{"begin":148,"end":153},"obj":"Body_part"}],"attributes":[{"id":"A19","pred":"uberon_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"crease mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11\nOur findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients.\n\nCONFLICT OF INTEREST\nPK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture"}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T141","span":{"begin":165,"end":173},"obj":"Disease"},{"id":"T142","span":{"begin":310,"end":318},"obj":"Disease"},{"id":"T143","span":{"begin":393,"end":401},"obj":"Disease"},{"id":"T144","span":{"begin":419,"end":423},"obj":"Disease"}],"attributes":[{"id":"A141","pred":"mondo_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A142","pred":"mondo_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A143","pred":"mondo_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A144","pred":"mondo_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"}],"text":"crease mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11\nOur findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients.\n\nCONFLICT OF INTEREST\nPK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture"}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T95","span":{"begin":43,"end":50},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T96","span":{"begin":209,"end":211},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T97","span":{"begin":341,"end":344},"obj":"http://purl.obolibrary.org/obo/PR_000001343"},{"id":"T98","span":{"begin":459,"end":462},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"crease mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11\nOur findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients.\n\nCONFLICT OF INTEREST\nPK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture"}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T110","span":{"begin":119,"end":132},"obj":"Chemical"},{"id":"T111","span":{"begin":300,"end":303},"obj":"Chemical"},{"id":"T113","span":{"begin":413,"end":415},"obj":"Chemical"},{"id":"T114","span":{"begin":456,"end":458},"obj":"Chemical"}],"attributes":[{"id":"A110","pred":"chebi_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"},{"id":"A111","pred":"chebi_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A112","pred":"chebi_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A113","pred":"chebi_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/CHEBI_74062"},{"id":"A114","pred":"chebi_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/CHEBI_74792"}],"text":"crease mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11\nOur findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients.\n\nCONFLICT OF INTEREST\nPK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture"}

    LitCovid-PD-GO-BP

    {"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T6","span":{"begin":104,"end":114},"obj":"http://purl.obolibrary.org/obo/GO_0046903"},{"id":"T7","span":{"begin":626,"end":631},"obj":"http://purl.obolibrary.org/obo/GO_0007568"}],"text":"crease mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11\nOur findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients.\n\nCONFLICT OF INTEREST\nPK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture"}

    LitCovid-PD-GlycoEpitope

    {"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T8","span":{"begin":119,"end":132},"obj":"GlycoEpitope"}],"attributes":[{"id":"A8","pred":"glyco_epitope_db_id","subj":"T8","obj":"http://www.glycoepitope.jp/epitopes/EP0510"}],"text":"crease mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11\nOur findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients.\n\nCONFLICT OF INTEREST\nPK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture"}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T153","span":{"begin":32,"end":208},"obj":"Sentence"},{"id":"T154","span":{"begin":209,"end":211},"obj":"Sentence"},{"id":"T155","span":{"begin":212,"end":319},"obj":"Sentence"},{"id":"T156","span":{"begin":320,"end":433},"obj":"Sentence"},{"id":"T157","span":{"begin":435,"end":455},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"crease mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11\nOur findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients.\n\nCONFLICT OF INTEREST\nPK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture"}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T54","span":{"begin":300,"end":303},"obj":"Phenotype"}],"attributes":[{"id":"A54","pred":"hp_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/HP_0020103"}],"text":"crease mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11\nOur findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients.\n\nCONFLICT OF INTEREST\nPK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture"}